Part XIII. Systemic antifungal therapy.
Until the last decade of the 20th century, intravenous amphotericin B deoxycholate was the only agent available to treat the relatively rare occurrence of serious systemic fungal infections. In response to an explosion in the incidence of systemic fungal infections, within a 15 year period, four new classes of antifungal agents were introduced: the triazoles, liposomal amphotericin B preparations, an allylamine, and echinocandins (Table 1). So an updated review of antifungal therapy is in order.
Busse
Kristin H
KH
Infectious Diseases Secton, Oklahoma City, OK 73190, USA.
Gentry
Chris A
CA
Bronze
Michael S
MS
Greenfield
Ronald A
RA
D000935:Antifungal Agents / Q000145:classification* / Q000627:therapeutic use*; D020314:Central Nervous System Fungal Infections / Q000188:drug therapy*; D006801:Humans; D008172:Lung Diseases, Fungal / Q000188:drug therapy*
D000935:Antifungal Agents